Atea Pharmaceuticals (AVIR) risk factors, FY2024 10-K

Risks Related to Our Financial Condition and Capital Requirements

1. 01We have a limited operating history and no history of successfully developing or commercializing any approved antiviral products, which may make it difficult to evaluate the success of our business to date and to assess the prospects for our future viability
2. 02If we successfully develop and obtain approval of any product candidate, we will need to transition from a company with a research and development focus to a company capable of executing commercial activities. We may not be successful in this transition
3. 03incur continuing and increasing legal, accounting and other expenses in operating our business as a public company
4. 04We may require substantial additional financing, which may not be available on acceptable terms, or at all. A failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our product development or commercialization efforts
5. 05development. In addition, attempting to secure additional financing could divert the time and attention of our management from day-to-day activities and may harm our product candidate development efforts
6. 06the continued costs of operating as a public company
7. 07We may engage in strategic collaborations or other transactions that could disrupt our business, cause dilution to our stockholders, reduce our financial resources, and subject us to other risks
8. 08We have not generated any revenue from product sales and may not be able to achieve profitability
9. 09our ability to establish, maintain, protect and enforce intellectual property rights in and to our HCV product candidate or any future product candidates
10. 10We maintain our cash at financial institutions, often in balances that exceed federally insured limits
11. 11As of December 31, 2024, we had US federal and state net operating loss carryforwards (“NOLs”), of $63.3 million and $98.7 million, respectively
12. 12arising from previous ownership changes, and if we undergo an ownership change, our ability to utilize NOLs (to the extent not previously utilized) and research and development credit carryforwards could be further limited by Sections 382 and 383 of the Code
13. 13alternatives successfully commercialized or widely accepted in the marketplace. There are currently approved and well established oral antiviral HCV products against which we would be required to compete if the regimen of bemnifosbuvir and ruzasvir is approved
14. 14In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate’s clinical development, and may vary among jurisdictions, which may cause delays in the approval or the decision not to approve an application
15. 15the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval
16. 16Clinical development, including enrollment of patients in clinical trials, is an expensive, lengthy and uncertain process. We may encounter substantial delays and costs in our clinical trials, or may not be able to conduct or complete our clinical trials on the timelines we expect, if at all
17. 17third parties being unwilling or unable to satisfy their contractual obligations to us
18. 18CTR. If we or our third-party service providers, such as CROs, encounter difficulties or are unable to comply with the CTR requirements our developments plans would be adversely impacted
19. 19For the treatment of HCV, we are currently developing bemnifosbuvir in combination with ruzasvir, a product candidate that has not yet been approved for marketing by the FDA or similar foreign regulatory authorities
20. 20Our product candidates may be associated with serious adverse events, undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential or result in significant negative consequences
21. 21If any serious adverse events occur, clinical trials or commercial distribution of any product we successfully develop could be suspended or terminated, and our business could be seriously harmed
22. 22If we encounter difficulties enrolling and retaining enrolled patients in our clinical trials and having patients comply with the clinical trial protocol, our clinical development activities could be delayed or otherwise adversely affected
23. 23other factors outside of our control, such as political unrest, war, terrorism and the occurrence of a global health crisis similar to COVID-19 which, among other things, created substantial burdens on healthcare providers who were required to prioritize immediate critical patient care over clinical research
24. 24Delays in patient enrollment may result in increased costs or may affect the timing or outcome of our ongoing and planned clinical trials, which could prevent completion or commencement of these trials and adversely affect our ability to advance the development of our product candidates
25. 25A Fast Track designation by the FDA may not lead to a faster development or regulatory review or approval process, and does not increase the likelihood that our product candidates will receive marketing approval
26. 26We currently conduct clinical trials, and may in the future choose to conduct additional clinical trials, of our product candidates in sites outside the US, and the FDA may not accept data from trials conducted in foreign locations
27. 27Interim, “topline” and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data
28. 28Part of our strategy involves identifying novel product candidates. For example, we are currently engaged in internal efforts to identify product candidates for the treatment of respiratory and other diseases resulting from infection with single stranded RNA viruses
29. 29We may focus on potential product candidates that may prove to be unsuccessful and we may have to forego opportunities to develop other product candidates that may prove to be more successful
30. 30provide the missing data and will never have to. Although a marketing authorization “under exceptional circumstances” is granted definitively, the risk-benefit balance of the medicinal product is reviewed annually and the marketing authorization may be withdrawn where the risk-benefit ratio is no longer favorable
31. 31Even if we complete the necessary preclinical studies and clinical trials, the marketing approval process is expensive, time-consuming and uncertain and may prevent us or any future collaboration partners from obtaining approvals for the commercialization of any product candidate we develop
32. 32substantially revised before adoption, which is not anticipated before early 2026. The revisions may however have a significant impact on the pharmaceutical industry and our business in the long term
33. 33Even if we obtain FDA approval of any of our product candidates, we may never obtain approval or commercialize such products outside of the US, which would limit our ability to realize their full market potential
34. 34Even if a current or future product candidate receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success
35. 35If the market opportunities for our product candidates are smaller than we believe they are or any approval we obtain is based on a narrower definition of the patient population, our business may suffer
36. 36Our insurance policies are expensive and protect us only from some business risks, which leaves us exposed to significant uninsured liabilities
37. 37Our business and operations may suffer in the event of information technology system failures, cyberattacks, or deficiencies, which could materially affect our results

Risks Related to Healthcare Laws and Other Legal Compliance Matters

1. 38We are subject to extensive and costly government regulation
2. 39Enacted and future healthcare legislation and policies may increase the difficulty and cost for us to commercialize our product candidates and could adversely affect our business
3. 40Since its enactment, there have been judicial, Congressional and executive challenges to certain aspects of the ACA. On June 17, 2021, the US Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA
4. 41Enacted and future legislation and policies may increase the difficulty and cost for us to obtain marketing approval of our product candidates and could adversely affect our business
5. 42Even if we obtain regulatory approval for a product candidate, our products will remain subject to regulatory scrutiny and post-marketing requirements
6. 43seize or detain products, or require a product recall
7. 44The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses
8. 45Our business operations and current and future relationships with clinical trial investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties
9. 46similar healthcare laws and regulations in the EU and other jurisdictions, including reporting requirements detailing interactions with and payments to healthcare providers
10. 47We face potential liability related to the privacy of health information we obtain from clinical trials sponsored by us
11. 48We are subject to environmental, health and safety laws and regulations, and we may become exposed to liability and substantial expenses in connection with environmental compliance or remediation activities
12. 49We and our employees are increasingly utilizing social media tools as a means of communication both internally and externally

Risks Related to Commercialization

1. 50Developments by competitors may render our products or technologies obsolete or non-competitive or may reduce the size of our markets
2. 51launching, marketing and selling products
3. 52For the diseases that we are targeting, significant competition exists from approved and authorized oral treatments as well as other treatments in development. The approved drugs, particularly for HCV, are well-established products and are widely-accepted by physicians, patients and third-party payors
4. 53more effective, have fewer or less severe side effects, are more convenient, or are less expensive than any products that we may develop or that would render any products that we may develop obsolete or noncompetitive, which would have a material adverse effect on our business and operations
5. 54We have limited personnel and limited infrastructure for the sales, marketing or distribution of products, and no experience as a company in commercializing a product candidate. The cost of building and maintaining such an organization may exceed the cost-effectiveness of doing so
6. 55In those territories where we engage a collaborator to commercialize our products in whole or in part our sales will depend on the collaborator’s strategic interest in the product and such collaborator’s ability to successfully commercialize the product
7. 56Our future growth may depend, in part, on our ability to penetrate foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties
8. 57Foreign sales of any product for which we obtain approval could also be adversely affected by the imposition of governmental controls, political and economic instability, trade restrictions and changes in tariffs
9. 58production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad
10. 59Potential product liability lawsuits against us could cause us to incur substantial liabilities and limit commercialization of any products that we may develop

Risks Related to Manufacturing and our Dependence on Third Parties

1. 60the misappropriation or unauthorized disclosure of our intellectual property or other proprietary information, including our trade secrets and know-how
2. 61Our third-party manufacturers may be unable to successfully scale up manufacturing of our product candidates in sufficient quality and quantity in a timely manner, if at all, which may impair the clinical advancement and commercialization of our product candidates
3. 62commercially reasonable terms, we may not be able to develop our product candidates and commercialize our products successfully
4. 63We rely on third parties to conduct our preclinical studies and clinical trials. Any failure by a third-party to conduct the clinical trials according to GCPs and in a timely manner may delay or prevent our ability to seek or obtain regulatory approval for or commercialize our product candidates
5. 64product revenue from any collaborations will depend on our collaborators’ abilities to successfully perform the functions assigned to them. We cannot predict the success of any collaboration that we enter into
6. 65collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all
7. 66Data provided by collaborators and others upon which we rely that have not been independently verified could turn out to be false, misleading or incomplete
8. 67If our CMOs and CROs use hazardous materials in a manner that causes injury or violates applicable law, we may be liable for damages

Risks Related to Intellectual Property

1. 68Third-party claims of intellectual property infringement, misappropriation or other violation may result in substantial costs or prevent or delay our development and commercialization efforts
2. 69present claims in a manner that could cover our product candidates or the use of our product candidates. After issuance, the scope of patent claims remains subject to construction as determined by an interpretation of the law, the written disclosure in a patent and the patent’s prosecution history
3. 70Our products are subject to The Drug Price Competition and Patent Term Restoration Act of 1984, as amended (also referred to as the Hatch-Waxman Act), in the US, that can increase the risk of litigation with generic companies trying to sell our products, and may cause us to lose patent protection
4. 71Patent terms may be inadequate to protect our competitive position on our products for an adequate amount of time
5. 72The Hatch-Waxman Act in the US provides for the opportunity to seek a patent term extension on one selected patent for each of our products, and the length of that patent term extension, if at all, is subject to review and approval by the USPTO and the FDA
6. 73If we are unable to obtain licenses from third parties on commercially reasonable terms or at all, or fail to comply with our obligations under such agreements, our business could be harmed
7. 74Litigation and adversarial proceedings are expensive, time-consuming and if unsuccessful, can adversely affect our ability to sell our products when commercialized
8. 75Changes in patent laws and enforcement by courts and other authorities in the US and other jurisdictions may impact our ability to protect our patents
9. 76Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
10. 77We may not be able to enforce our intellectual property rights throughout the world
11. 78We rely on our ability to stop others from competing by enforcing our patents, however some jurisdictions may require us to grant licenses to third parties. Such compulsory licenses could be extended to include some of our product candidates, which may limit our potential revenue opportunities
12. 79If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed
13. 80Our proprietary rights may not adequately protect our technologies and product candidates, and intellectual property rights do not necessarily address all potential threats to our competitive advantage

Risks Related to Employee Matters, Managing Operations and Other Risks Related to Our Business

1. 81In the first quarter of 2025, in order to reduce costs and support longer term business sustainability, we implemented a reduction in our workforce
2. 82Our future success depends upon our ability to retain officers, directors and key employees and attract, retain and motivate qualified personnel
3. 83We do not carry key person life insurance on any officers or directors
4. 84We rely on consultants, advisors and third parties for the performance of critical aspects of our business operations
5. 85Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and share price
6. 86Our business could face adverse consequences as a result of the actions of activist shareholders

Risks Related to Our Common Stock

1. 87If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline, even if our business is doing well
2. 88Provisions in our restated certificate of incorporation and amended and restated bylaws and under Delaware law could make an acquisition of our Company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management
3. 89Our restated certificate of incorporation designates specific courts as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us
4. 90Raising additional capital may cause additional dilution to our stockholders, restrict our operations, require us to relinquish rights to our technologies or product candidates, and could cause our share price to fall
5. 91We or the third parties upon whom we depend may be adversely affected by natural disasters or pandemics and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster
6. 92Increased scrutiny of, and evolving expectations for ESG initiatives could increase our costs, harm our reputation, or otherwise adversely impact our business
7. 93Litigation against us could be costly and time-consuming to defend and could result in additional liabilities
8. 94The market price of our common stock has been volatile and may fluctuate substantially
9. 95the other factors described in this “Risk Factors” section
10. 96If we fail to maintain effective internal control over financial reporting and effective disclosure controls and procedures, we may not be able to accurately report our financial results in a timely manner or prevent fraud, which may adversely affect investor confidence in our company
11. 97Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud
12. 98Because we do not anticipate paying any cash dividends on our common stock in the foreseeable future, capital appreciation, if any, is likely to be your sole source of gain